TY - JOUR
T1 - SCN5A mutations in 442 neonates and children
T2 - Genotype-phenotype correlation and identification of higher-risk subgroups
AU - Baruteau, Alban Elouen
AU - Kyndt, Florence
AU - Behr, Elijah R.
AU - Vink, Arja S.
AU - Lachaud, Matthias
AU - Joong, Anna
AU - Schott, Jean Jacques
AU - Horie, Minoru
AU - Denjoy, Isabelle
AU - Crotti, Lia
AU - Shimizu, Wataru
AU - Bos, Johan M.
AU - Stephenson, Elizabeth A.
AU - Wong, Leonie
AU - Abrams, Dominic J.
AU - Davis, Andrew M.
AU - Winbo, Annika
AU - Dubin, Anne M.
AU - Sanatani, Shubhayan
AU - Liberman, Leonardo
AU - Kaski, Juan Pablo
AU - Rudic, Boris
AU - Kwok, Sit Yee
AU - Rieubland, Claudine
AU - Tfelt-Hansen, Jacob
AU - Van Hare, George F.
AU - Guyomarc'h-Delasalle, Béatrice
AU - Blom, Nico A.
AU - Wijeyeratne, Yanushi D.
AU - Gourraud, Jean Baptiste
AU - Marec, Hervé Le
AU - Ozawa, Junichi
AU - Fressart, Véronique
AU - Lupoglazoff, Jean Marc
AU - Dagradi, Federica
AU - Spazzolini, Carla
AU - Aiba, Takeshi
AU - Tester, David J.
AU - Zahavich, Laura A.
AU - Beauséjour-Ladouceur, Virginie
AU - Jadhav, Mangesh
AU - Skinner, Jonathan R.
AU - Franciosi, Sonia
AU - Krahn, Andrew D.
AU - Abdelsayed, Mena
AU - Ruben, Peter C.
AU - Yung, Tak Cheung
AU - Ackerman, Michael J.
AU - Wilde, Arthur A.
AU - Schwartz, Peter J.
AU - Probst, Vincent
N1 - Funding Information:
French Society of Cardiology (to A.-E.B.) a research grant the Foundation Bettencourt-Schueller (to A.-E.B.) and by research funds from Cardiac Risk in the Young (to A.-E.B., L.W., and E.R.B.); by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London (to J.P.K.); by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program (to M.J.A.); by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development, and the Royal Netherlands Academy of Sciences (CVON Predict to A.A.W.).
Publisher Copyright:
© The Author 2018.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Aims To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. Methods and results A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE. Conclusion In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.
AB - Aims To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. Methods and results A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE. Conclusion In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.
KW - Brugada syndrome
KW - Genotype-phenotype correlation
KW - Long QT syndrome
KW - Progressive cardiac conduction disorders
KW - SCN5A
KW - Sodium channelopathy
UR - http://www.scopus.com/inward/record.url?scp=85055420900&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehy412
DO - 10.1093/eurheartj/ehy412
M3 - Article
C2 - 30059973
AN - SCOPUS:85055420900
SN - 0195-668X
VL - 39
SP - 2879
EP - 2887
JO - European heart journal
JF - European heart journal
IS - 31
ER -